0
₹0 0
Nextgen Biotech

Call us:

menu

Pegasta 6mg - Pegfilgrastim Injection

  • Home
  • Pegasta 6mg - Pegfilgrastim Injection

Pegasta 6mg - Pegfilgrastim Injection

Pegasta 6mg is an injectable biologic medication used to reduce the risk of infection in patients undergoing chemotherapy by boosting white blood cell (neutrophil) production. It is a long-acting form of G-CSF (Granulocyte Colony-Stimulating Factor).

Select your size:

Choose Quantity:

-
+
+ Add To Cart
Add to wishlist
Share
Description Product Details
General Information:
Generic Name: Pegfilgrastim
Brand Name: Pegasta 6mg
Packing: Prefilled syringe, 0.6 mL
Strength: 6 mg
Manufacturer: [To be added/customized]
Form: Subcutaneous Injection
Category: Hematopoietic agent / Immunostimulant
Product Introduction:
Pegasta 6mg contains Pegfilgrastim, a pegylated form of filgrastim designed to stimulate the bone marrow to produce more neutrophils, a type of white blood cell. It is typically administered once per chemotherapy cycle to prevent neutropenia-related infections in cancer patients.
Uses:
Pegasta 6mg is used for:
  1. Prevention of neutropenia in patients undergoing chemotherapy
  2. Reduction of infection risk (febrile neutropenia)
  3. Supportive care during cancer treatment
  4. Increase neutrophil count in bone marrow disorders
  5. Use in stem cell transplantation support
  6. Management of radiation-induced bone marrow suppression (off-label)
Storage Instructions:
  1. Store at 2°C to 8°C (Refrigerated)
  2. Protect from light and freezing
  3. Allow the syringe to reach room temperature before injection
  4. Do not shake the syringe
  5. Keep out of reach of children
How It Works (Mechanism of Action):
Pegfilgrastim binds to specific receptors on hematopoietic cells in the bone marrow and stimulates the production and release of neutrophils. Its pegylated structure gives it a longer half-life, allowing once-per-cycle dosing compared to daily dosing with filgrastim.
Side Effects:
Common side effects:
  1. Bone pain
  2. Muscle and joint aches
  3. Headache
  4. Fatigue
  5. Redness or discomfort at the injection site
Serious side effects:
  1. Splenic rupture (rare but life-threatening)
  2. Acute respiratory distress syndrome (ARDS)
  3. Allergic reactions (rash, swelling, difficulty breathing)
  4. Capillary leak syndrome (very rare)
  5. Severe back or abdominal pain
Dosage (Typical Recommended Dose):
  1. Single dose of 6 mg subcutaneously once per chemotherapy cycle
  2. Administered at least 24 hours after chemotherapy completion
Method of Administration:
  1. Subcutaneous injection in the upper arm, thigh, or abdomen
  2. Should only be administered by a healthcare professional or under guidance
  3. Do not administer within 14 days before or 24 hours after chemotherapy
Precautions:
  1. Monitor for signs of splenic rupture (sharp left upper abdominal pain)
  2. Not recommended in patients with myeloid malignancies
  3. Regular complete blood counts (CBCs) should be performed
  4. Caution in patients with sickle cell disease or respiratory conditions
  5. Avoid use in pregnancy or breastfeeding unless absolutely necessary
Drug Interactions:
  1. No significant drug-drug interactions have been reported
  2. Should not be given concurrently with chemotherapy or radiation
  3. Avoid co-administration with other G-CSF agents
Allergies:
  1. Pegfilgrastim can cause serious allergic reactions, including anaphylaxis
  2. Symptoms may include rash, dizziness, throat swelling, or difficulty breathing
  3. Discontinue immediately if allergic reaction occurs and seek emergency care
Overdose Information:
  1. Overdose may lead to excessive white blood cell production
  2. Supportive treatment and close monitoring of WBC counts is advised
  3. No specific antidote exists
Missed Dose Instructions:
  1. Pegfilgrastim is typically a once-per-cycle dose, so consult your doctor immediately if a dose is missed
  2. Do not take additional doses unless instructed by a healthcare provider
Additional Notes:
  1. Patients should report unusual pain, fever, or shortness of breath immediately
  2. Bone pain can be managed with non-opioid analgesics
  3. Do not shake the syringe to preserve medicine integrity
  4. Ensure proper disposal of used syringes
  5. Consider using in combination with other supportive therapies during chemo
View More

In The Same Category

Cart